Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects

NCT02585804 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University Health Network, Toronto

Collaborators